Goldman says play defense with these stocks if you're worried about the AI bull failing

Goldman Sachs says defensive, quality stocks in health care and consumer staples could benefit if investors lower earnings-growth expectations as AI-related spending growth slows; it estimates AI capital spending contributes about half of S&P 500 earnings growth. Its screen includes Tyson Foods, with an 11% trailing four-quarter free cash flow yield and shares down nearly 17% over six months, and CVS Health, with a 9% free cash flow yield, shares up 15% year to date but down 15% over the past three months. Goldman’s base case still expects earnings growth and anticipates weaker energy prices and lower interest rates in 2027 could support household spending.

Analysis

The useful signal is portfolio construction, not a new earnings catalyst: if AI-led growth expectations are marked down, crowded growth exposure can unwind faster than fundamentals change, creating relative demand for overlooked cash-generative names. But the screen does not make TSN and CVS interchangeable defensives. TSN remains exposed to protein pricing, feed costs, and operating execution; a broad staples bid can mask company-specific margin weakness. CVS’s cash yield may attract value buyers, but it is not a clean rate hedge: reimbursement, policy, and execution risks can overwhelm any benefit from lower discount rates. Treat the stated cash-flow yields as screening inputs, not proof that the cash flows are durable.

Over days to weeks, positioning and rates are the likely drivers; a rotation can reverse sharply if yields rise or AI spending expectations stabilize. Over 1–3 months, verify reported free cash flow, segment trends, and guidance before adding exposure. The 6–18 month upside case requires easing energy and financing pressure to support consumers without worsening company-specific input or reimbursement economics. The contrarian risk is that investors buy the defensive label while underestimating those idiosyncratic exposures. No valuation data or independently confirmed cash-flow durability is supplied, so the evidence supports a watchlist and selective relative-value exposure, not a broad defensive allocation.

Key Decisions for Investors

• Avoid chasing a one-day defensive rotation. Consider a staged, modest TSN position only if earnings commentary confirms cash conversion and protein/feed-cost trends are not deteriorating; reassess if free cash flow weakens or guidance is cut.
• Keep CVS on an event-driven watchlist rather than treating its yield as a standalone buy signal. Verify cash-flow composition and upcoming reimbursement, policy, and operating updates; a deterioration in those metrics would falsify the catch-up thesis even if rates fall.
• For a 1–3 month hedge, express the view as a small long-defensive/short-high-beta-growth relative-value trade rather than an outright market call, sizing against the risk that AI earnings expectations recover or rates rise. Define the exit by relative performance and fundamentals, not the Goldman screen alone.
• Track Treasury yields, energy prices, and positioning: falling rates and energy costs would support the consumer-facing catch-up case over 6–18 months; renewed rises in either, or evidence of slowing household demand, argue against extending the trade.